Your session is about to expire
← Back to Search
Monoclonal Antibodies
VIP152 for Chronic Lymphocytic Leukemia
Phase 1
Waitlist Available
Research Sponsored by Vincerx Pharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
Study Summary
This trial will test the safety and effectiveness of VIP152 in patients with CLL or Richter Syndrome.
Eligible Conditions
- Chronic Lymphocytic Leukemia
- Non-Hodgkin's Lymphoma
- Richter Syndrome
- MYC Amplification
- MYC Overexpression
- MYC Translocation
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Safety and Tolerability
Secondary outcome measures
Assessment of pharmacokinetics (PK) of VIP152
Duration of Response
Overall Response Rate
+2 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: VIP152 in combination with BTKiExperimental Treatment2 Interventions
Investigating VIP152 in combination with a BTKi in patients with CLL
Group II: Monotherapy of VIP152Experimental Treatment1 Intervention
Investigating VIP152 in a monotherapy cohort in patients with high-risk CLL and Richter Syndrome
Find a Location
Who is running the clinical trial?
Vincerx Pharma, Inc.Lead Sponsor
3 Previous Clinical Trials
170 Total Patients Enrolled
Vincerx Study DirectorStudy DirectorVincerx Pharma, Inc.
3 Previous Clinical Trials
170 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Monotherapy of VIP152
- Group 2: VIP152 in combination with BTKi
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger